Stanford scientists have discovered that blocking an immune receptor signal can lead to increased fat uptake and weight reduction in patients suffering from obesity and associated diseases.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Stanford researchers have developed potent protein Kinase inhibitors for inhibition of pathological activity of protein kinases involved in cell death, inflammation and cancer.
The blood-brain barrier is a huge challenge when it comes to the delivery of therapeutic proteins to treat genetic diseases, injury, and neurodegenerative diseases.